# Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

> **NCT03301038** · PHASE2 · RECRUITING · sponsor: **Children's Hospital of Philadelphia** · enrollment: 60 (estimated)

## Conditions studied

- Idiopathic Infantile Hypercalcaemia - Severe Form
- Genetic Disease
- Hypercalcemia, Idiopathic, of Infancy
- Hypercalciuric Hypercalcemia
- Idiopathic Infantile Hypercalcemia - Mild Form
- Hypercalciuria

## Interventions

- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT03301038
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-25
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301038, "Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03301038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*